Статья

Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

Z. Papp, P. Agostoni, J. Alvarez, D. Bettex, S. Bouchez, D. Brito, V. Černý, J. Comin-Colet, M. Crespo-Leiro, J. Delgado, I. Édes, A. Eremenko, D. Farmakis, F. Fedele, C. Fonseca, S. Fruhwald, M. Girardis, F. Guarracino, V. Harjola, M. Heringlake, A. Herpain, L. Heunks, T. Husebye, V. Ivancan, K. Karason, S. Kaul, M. Kivikko, J. Kubica, J. Masip, S. Matskeplishvili, A. Mebazaa, M. Nieminen, F. Oliva, J. Papp, J. Parissis, A. Parkhomenko, P. Põder, G. Pölzl, A. Reinecke, S. Ricksten, H. Riha, A. Rudiger, T. Sarapohja, R. Schwinger, W. Toller, L. Tritapepe, C. Tschöpe, G. Wikström, D. Lewinski, B. Vrtovec, P. Pollesello,
2020

Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2020-01-01

Метаданные

Об авторах
  • Z. Papp
    Debreceni Egyetem Általános Orvostudományi Kar
  • P. Agostoni
    IRCCS Centro Cardiologico Monzino
  • J. Alvarez
    Universidad de Santiago de Compostela
  • D. Bettex
    UniversitatsSpital Zurich
  • S. Bouchez
    University Hospital of Ghent
  • D. Brito
    Universidade de Lisboa
  • V. Černý
    Univerzita Jana Evangelisty Purkyne v Ústí nad Labem
  • J. Comin-Colet
    Hospital Universitari de Bellvitge
  • M. Crespo-Leiro
    Universidade da Coruña
  • J. Delgado
    Hospital Universitario 12 de Octubre
  • I. Édes
    Debreceni Egyetem Általános Orvostudományi Kar
  • A. Eremenko
    Sechenov First Moscow State Medical University
  • D. Farmakis
    University of Cyprus
  • F. Fedele
    Sapienza Università di Roma
  • C. Fonseca
    Hospital São Francisco Xavier
  • S. Fruhwald
    Medizinische Universität Graz
  • M. Girardis
    Azienda Ospedaliero - Universitaria di Modena Policlinico
  • F. Guarracino
    Azienda Ospedaliera-Universitaria Pisana
  • V. Harjola
    Helsinki University Hospital
  • M. Heringlake
    Universität zu Lübeck
  • A. Herpain
    Hospital Erasme
  • L. Heunks
  • T. Husebye
    Ulleval University Hospital
  • V. Ivancan
    University of Zagreb School of Medicine
  • K. Karason
    Sahlgrenska Universitetssjukhuset
  • S. Kaul
    University Health Service
  • M. Kivikko
    Orion Corporation
  • J. Kubica
    Uniwersytet Mikołaja Kopernika w Toruniu
  • J. Masip
    Universitat de Barcelona
  • S. Matskeplishvili
    Lomonosov Moscow State University
  • A. Mebazaa
    AP-HP Assistance Publique - Hopitaux de Paris
  • M. Nieminen
    Sydäntutkimussäätiö
  • F. Oliva
    Ospedale Niguarda, Milan
  • J. Papp
    Szegedi Tudományegyetem (SZTE)
  • J. Parissis
    Attikon University Hospital
  • A. Parkhomenko
    National Scientific Center M.D. Strazhesko Institute of Cardiology
  • P. Põder
    North Estonia Medical Centre
  • G. Pölzl
    Medizinische Universitat Innsbruck
  • A. Reinecke
    Universitätsklinikum Schleswig-Holstein Campus Kiel
  • S. Ricksten
    Sahlgrenska Universitetssjukhuset
  • H. Riha
    Institutu Klinické a Experimentální Medicíny
  • A. Rudiger
  • T. Sarapohja
    Orion Corporation
  • R. Schwinger
    Universität Regensburg
  • W. Toller
    Medizinische Universität Graz
  • L. Tritapepe
    Azienda Ospedaliera San Camillo Forlanini
  • C. Tschöpe
    Charité – Universitätsmedizin Berlin
  • G. Wikström
    Uppsala Universitet
  • D. Lewinski
    Medizinische Universität Graz
  • B. Vrtovec
    Univerzitetni Klinični Center Ljubljana
  • P. Pollesello
    Orion Corporation
Название журнала
  • Journal of Cardiovascular Pharmacology
Том
  • 76
Выпуск
  • 1
Страницы
  • 4-22
Номер гранта
  • undefined
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus